Abstract 【Objective】To investigate the relationship between the expression of E2F2 and the prognosis and immune invasion of prostate cancer. 【Methods】Based on the CancerGenome Atlas (TCGA) database, the expression of E2F2 in prostate cancer was analyzed. The correlation between the expression level of E2F2 and the prognosis of prostate cancer patients was analyzed by gene set enrichment analysis and immune infiltration analysis. The ROC curve was used to analyze the diagnostic value of E2F2 in prostate cancer. 【Results】The expression level of E2F2 in prostate cancer tissues was higher than that in normal prostate tissues (P<0.001); The expression level of E2F2 in prostate cancer tissues was higher than that in normal tissues adjacent to prostate cancer (P<0.001). The expression level of E2F2 in T3~4 stage prostate cancer patients was higher than that in normal tissues and T2 stage, and that in N1 stage was higher than that in normal tissues and N0 stage (P<0.05); There was no significant difference in E2F2 expression among patients with different M stages and different prognosis (P>0.05). Kaplan Meier survival analysis showed that the expression level of E2F2 was negatively correlated with the overall survival rate and progression free interval of prostate cancer patients (all P<0.05); There was no significant correlation between E2F2 expression level and disease specific survival rate of prostate cancer patients (P>0.05). ROC curve analysis showed that the AUC of E2F2 in diagnosing prostate cancer was 0.731 (95%CI:0.653~0.809). Spearman correlation analysis showed that the expression level of E2F2 was positively correlated with T-helper lymphocyte 2, T-helper lymphocyte, dendritic cells and T-cell enrichment group (all P<0.05); The expression level of E2F2 was negatively correlated with the concentration of natural killer cells and mast cells (all P<0.05). 【Conclusion】The expression level of E2F2 in prostate cancer patients is significantly increased, and the overexpression of E2F2 is closely related to poor prognosis and cellular immune infiltration.
BAI Yao,CHEN Gui-Heng,MAO Zheng. Correlation between E2F2 Expression Level and Prognosis and Immune Infiltration in Patients with Prostate Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(12): 1803-1805.
[1] SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30. [2] HE Y,XU W,XIAO Y T,et al. Targeting signaling pathways in prostate cancer:mechanisms and clinical trials[J].Signal Transduct Target Ther,2022,7(1):198. [3] ENGELAND K. Cell cycle regulation:p53-p21-RB signaling[J].Cell Death Differ,2022,29(5):946-960. [4] ZHOU Q,ZHANG F,HE Z,et al.E2F2/5/8 Serve as potential prognostic biomarkers and targets for human ovarian cancer[J].Front Oncol,2019,9:161. [5] SONG H,ZHANG Y,LIU N,et al. Let-7b inhibits the malignant behavior of glioma cells and glioma stem-like cells via downregulation of E2F2[J].J Physiol Biochem,2016,72(4):733-744. [6] ZHAO H,TANG W,CHEN X,et al. The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells[J].Biochem Biophys Res Commun,2017,493(1):77-84. [7] HE Y,XU W,XIAO Y T,et al. Targeting signaling pathways in prostate cancer:mechanisms and clinical trials[J].Signal Transduct Target Ther,2022,7(1):198. [8] MA X R,EDMUND SIM U H,PAULINE B,et al. Overexpression of WNT2 and TSG101 genes in colorectal carcinoma[J].Trop Biomed,2008,25(1):46-57. [9] CHONG J L,WENZEL P L,SÁENZ-ROBLES M T,et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells[J].Nature,2009,462(7275):930-934. [10] HUAN J,WANG L,XING L,et al. Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2)[J].Gene,2014,533(1):346-355. [11] OPAVSKY R,TSAI S Y,GUIMOND M,et al. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis[J].Proc Natl Acad Sci U S A,2007,104(39):15400-15405. [12] LI P,XU H,YANG L,et al. E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1[J].Cell Death Dis,2022,13(1):77.
2022, Vol. 39 
